INFLECTIS BIOSCIENCE

IFB-088 Shows Promise in Phase 2 Trial for Bulbar-Onset ALS, Demonstrating Slower Disease Progression

- Phase 2 clinical trial demonstrates IFB-088 (icerguastat) meets primary safety endpoint and shows significant reduction in disease progression for bulbar-onset ALS patients. - Treated patients in the per protocol population showed notably slower decline, losing 0.95 points monthly on ALSFRS-R compared to 1.42 points in the placebo group. - Biomarker data confirms IFB-088's mechanism of action through integrated stress response activation and oxidative stress reduction, supporting further development.